Mississippi Nurse Denied Drug Prescribing Privileges by DEA
Published Date: 9/30/2025
Notice
Summary
Jody Adams, a nurse practitioner from Mississippi, tried to get a DEA registration but got denied because she issued three controlled substance prescriptions without proper authorization. This decision means she can’t legally prescribe these drugs, protecting public safety. The denial is final, and no hearing was requested, so the decision is effective immediately with no money penalties mentioned.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Denied for Jody Adams
The Drug Enforcement Administration denied the DEA registration application (Control No. W24008696M) of Jody Adams, N.P., and also denied any other pending registration application of hers in Mississippi. The record shows she admitted issuing three controlled-substance prescriptions without an active DEA registration between January 18, 2023 and January 29, 2024 (two prescriptions for testosterone, a Schedule III drug, and one for pregabalin, a Schedule V drug). The denial is effective October 30, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-19061, Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to the Listing and Trading of Shares of the 7RCC Spot Bitcoin and Carbon Credit Futures ETF
NYSE Arca is switching how the 7RCC Spot Bitcoin and Carbon Credit Futures ETF shares are listed and traded, moving from a special rule to a more general one. This change affects investors trading these shares and takes effect immediately, aiming to make trading smoother and more flexible. No new fees or costs are introduced, but the update could impact how quickly and easily shares are bought and sold.
Next: 2025-19064, Self-Regulatory Organizations; National Securities Clearing Corporation; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend NSCC Rule 22 (Suspension of Rules)
The National Securities Clearing Corporation (NSCC) just updated its Rule 22, which lets them pause certain rules when needed. This change affects NSCC and its sister agencies, helping them act faster and smarter during unusual situations. The update is already in effect, so members should be ready for quicker decisions that could impact how money moves in the market.